Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis

GIFT‐I is a phase 3 trial evaluating the efficacy and safety of a 12‐week regimen of coformulated ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) for treatment of Japanese hepatitis C virus genotype 1b–infected patients. It consists of a double‐blind, placebo‐controlled substudy of patients withou...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumada, Hiromitsu, Chayama, Kazuaki, Rodrigues, Lino, Suzuki, Fumitaka, Ikeda, Kenji, Toyoda, Hidenori, Sato, Ken, Karino, Yoshiyasu, Matsuzaki, Yasushi, Kioka, Kiyohide, Setze, Carolyn, Pilot‐Matias, Tami, Patwardhan, Meenal, Vilchez, Regis A., Burroughs, Margaret, Redman, Rebecca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Viral Hepatitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049673/
https://www.ncbi.nlm.nih.gov/pubmed/26147154
http://dx.doi.org/10.1002/hep.27972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049673/
https://www.ncbi.nlm.nih.gov/pubmed/26147154
http://dx.doi.org/10.1002/hep.27972

Ejemplares similares